Standard Standard

Mean platelet volume in patients with rheumatoid arthritis : the effect of anti-TNF-α therapy. / Gasparyan, Armen Yuri; Sandoo, Aamer; Stavropoulos-Kalinoglou, Antonios; Kitas, George D.

In: Rheumatology international, Vol. 30, No. 8, 06.2010, p. 1125-9.

Research output: Contribution to journalArticle

HarvardHarvard

Gasparyan, AY, Sandoo, A, Stavropoulos-Kalinoglou, A & Kitas, GD 2010, 'Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-α therapy', Rheumatology international, vol. 30, no. 8, pp. 1125-9. https://doi.org/10.1007/s00296-009-1345-1

APA

Gasparyan, A. Y., Sandoo, A., Stavropoulos-Kalinoglou, A., & Kitas, G. D. (2010). Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-α therapy. Rheumatology international, 30(8), 1125-9. https://doi.org/10.1007/s00296-009-1345-1

CBE

Gasparyan AY, Sandoo A, Stavropoulos-Kalinoglou A, Kitas GD. 2010. Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-α therapy. Rheumatology international. 30(8):1125-9. https://doi.org/10.1007/s00296-009-1345-1

MLA

VancouverVancouver

Gasparyan AY, Sandoo A, Stavropoulos-Kalinoglou A, Kitas GD. Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-α therapy. Rheumatology international. 2010 Jun;30(8):1125-9. https://doi.org/10.1007/s00296-009-1345-1

Author

Gasparyan, Armen Yuri ; Sandoo, Aamer ; Stavropoulos-Kalinoglou, Antonios ; Kitas, George D. / Mean platelet volume in patients with rheumatoid arthritis : the effect of anti-TNF-α therapy. In: Rheumatology international. 2010 ; Vol. 30, No. 8. pp. 1125-9.

RIS

TY - JOUR

T1 - Mean platelet volume in patients with rheumatoid arthritis

T2 - the effect of anti-TNF-α therapy

AU - Gasparyan, Armen Yuri

AU - Sandoo, Aamer

AU - Stavropoulos-Kalinoglou, Antonios

AU - Kitas, George D

PY - 2010/6

Y1 - 2010/6

N2 - A number of mediators are involved in the inflammatory processes that affect joints and vascular wall of patients with rheumatoid arthritis (RA). Tumour necrosis factor alpha (TNFa) is one such mediator, and it is widely regarded as an important target for anti-rheumatic treatment. Most recent studies show that anti-TNFa medication suppresses inflammation and reduces overall activity of RA. The aim of the current study was to investigate changes of mean platelet volume (MPV) in response to the 3-month anti-TNFa therapy in RA. Twenty-one RA patients without established cardiovascular disease were recruited for anti-TNFa therapy and underwent thorough clinical and laboratory evaluation at baseline, 2 weeks, and 12 weeks. Anti-TNFa therapy resulted in a significant (p = 0.01) increase in MPV over the duration of the study (7.7 +/- 0.9, 7.8 +/- 1.1, and 8.4 +/- 1.1 fL at baseline, 2 weeks, and 12 weeks, respectively). The results of the study expand perspectives of the use of MPV in conditions associated with high-grade inflammation, particularly RA, for monitoring anti-inflammatory treatment. More prospective studies with large numbers of patients are warranted to ascertain associations of high and low values of MPV with diverse markers of inflammation and vascular pathology.

AB - A number of mediators are involved in the inflammatory processes that affect joints and vascular wall of patients with rheumatoid arthritis (RA). Tumour necrosis factor alpha (TNFa) is one such mediator, and it is widely regarded as an important target for anti-rheumatic treatment. Most recent studies show that anti-TNFa medication suppresses inflammation and reduces overall activity of RA. The aim of the current study was to investigate changes of mean platelet volume (MPV) in response to the 3-month anti-TNFa therapy in RA. Twenty-one RA patients without established cardiovascular disease were recruited for anti-TNFa therapy and underwent thorough clinical and laboratory evaluation at baseline, 2 weeks, and 12 weeks. Anti-TNFa therapy resulted in a significant (p = 0.01) increase in MPV over the duration of the study (7.7 +/- 0.9, 7.8 +/- 1.1, and 8.4 +/- 1.1 fL at baseline, 2 weeks, and 12 weeks, respectively). The results of the study expand perspectives of the use of MPV in conditions associated with high-grade inflammation, particularly RA, for monitoring anti-inflammatory treatment. More prospective studies with large numbers of patients are warranted to ascertain associations of high and low values of MPV with diverse markers of inflammation and vascular pathology.

KW - Aged

KW - Arthritis, Rheumatoid

KW - Blood Platelets

KW - Blood Sedimentation

KW - Female

KW - Humans

KW - Immunosuppressive Agents

KW - Male

KW - Middle Aged

KW - Platelet Count

KW - Treatment Outcome

KW - Tumor Necrosis Factor-alpha

KW - Journal Article

U2 - 10.1007/s00296-009-1345-1

DO - 10.1007/s00296-009-1345-1

M3 - Article

VL - 30

SP - 1125

EP - 1129

JO - Rheumatology international

JF - Rheumatology international

SN - 0172-8172

IS - 8

ER -